IL-34 Protéine

N° du produit ABIN2666711

Cette protéine Recombinant IL-34 est exprimée dans CHO Cells.

Aperçu rapide pour IL-34 Protéine (ABIN2666711)

Antigène: IL-34 (IL34) (Interleukin 34 (IL34))

Type de proteíne: Recombinant

Origine: Humain

Source: CHO Cells

Application: Flow Cytometry (FACS)

Détail du produit

Stérilité: 0.22 μm filtered

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored from -20 °C to -70 °C. Stock solutions can also be prepared at 50-100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2-1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in 10 mM NaH2PO4, 0.5 M NaCl, pH 7.4.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.

Stock: -20 °C

Stockage commentaire: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Détail du antigène

Antigène: IL-34 (IL34) (Interleukin 34 (IL34))

Autre désignation: IL-34

Sujet: Human IL-34 shares a sequence identity of 99.6 % , 72 % and 71 % with chimpanzee, rat, and mouse IL-34, respectively, on the amino acid level. The IL-34 gene is syntenic in the human, chimpanzee, rat, and mouse genomes. IL-34 has no apparent consensus structural domain or motif, and does not share sequence homology with M-CSF, nevertheless, it binds to the CSFR. These two cytokines are not identical in biological activity and signal activation. IL-34 and CSF show an equivalent ability to support cell growth or survival. However, these cytokines have differing ability to induce the production of chemokines (MCP-1 and eotaxin-2) in primary macrophages, the morphological change in TF-1-fms cells, and the migration of J774A.1 cells. The use of monoclonal antibodies against the CSFR suggests a differential domain binding in the receptor to IL-34 and CSF and, as a result, different bioactivities and signal activation kinetics/strength are produced for these cytokines.

Pathways: Signalisation RTK